<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04671849</url>
  </required_header>
  <id_info>
    <org_study_id>SIM1803-1A-NTRK-0101</org_study_id>
    <nct_id>NCT04671849</nct_id>
  </id_info>
  <brief_title>An Open Label, Multi-center, Phase I Clinical Study to Evaluate the Safety, Effectiveness and Pharmacokinetic Characteristics of SIM1803-1A in Patients With Locally Advanced/Metastatic Solid Tumors With NTRK, ROS1 or ALK Gene Fusion Mutations.</brief_title>
  <official_title>An Open Label, Multi-center, Phase I Clinical Study to Evaluate the Safety, Effectiveness and Pharmacokinetic Characteristics of SIM1803-1A in Patients With Locally Advanced/Metastatic Solid Tumors With NTRK, ROS1 or ALK Gene Fusion Mutations.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Simcere Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu Simcere Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study is done to test the safety, effectiveness and pharmacokinetic&#xD;
      characteristics of SIM1803-1A in patients with locally advanced/metastatic solid tumors with&#xD;
      NTRK, ROS1 or ALK gene fusion mutations. The cancer must have a change in a particular gene&#xD;
      (NTRK1, NTRK2, NTRK3, ROS1 or ALK). SIM1803-1A is a drug that blocks the actions of these&#xD;
      NTRK/ ROS1 /ALK genes in cancer cells and can therefore be used to treat cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 21, 2020</start_date>
  <completion_date type="Anticipated">January 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>5 years</time_frame>
    <description>Number of participants with adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of adverse events</measure>
    <time_frame>5 years</time_frame>
    <description>Severity of adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose</measure>
    <time_frame>5 years</time_frame>
    <description>Maximum tolerated dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended dose for dose expansion</measure>
    <time_frame>5 years</time_frame>
    <description>Recommended dose for dose expansion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum concentration of SIM1803-1A in plasma (Cmax)</measure>
    <time_frame>Predose and 0.25, 0.5, 1, 2, 4, 8，12，24and 48 hours after drug administration on Days 1 and 8 of Cycle 1（each cycle is 21 days）</time_frame>
    <description>Maximum concentration of SIM1803-1A in plasma (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve of SIM1803-1A in plasma from time 0 to 24 hours in fasted state (AUC(0-24)_fasted)</measure>
    <time_frame>Up to 1 day</time_frame>
    <description>Area under the concentration-time curve of SIM1803-1A in plasma from time 0 to 24 hours in fasted state (AUC(0-24)_fasted)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve of SIM1803-1A in plasma from time 0 to infinity in fasted state (AUC_fasted)</measure>
    <time_frame>Up to 3 days</time_frame>
    <description>Area under the concentration-time curve of SIM1803-1A in plasma from time 0 to infinity in fasted state (AUC_fasted)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Number of participants with treatment-emergent adverse events (TEAEs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to maximum concentration of SIM1803-1A in plasma (Tmax)</measure>
    <time_frame>Predose and 0.25, 0.5, 1, 2, 4, 8，12，24and 48 hours after drug administration on Days 1 and 8 of Cycle 1（each cycle is 21 days)</time_frame>
    <description>Time to maximum concentration of SIM1803-1A in plasma (Tmax)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>Up to 60 months</time_frame>
    <description>Overall Response Rate (ORR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Up to 60 months</time_frame>
    <description>Duration of Response (DOR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression-free survival（PFS）</measure>
    <time_frame>Up to 60 months</time_frame>
    <description>progression-free survival（PFS）</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">243</enrollment>
  <condition>Advanced or Metastatic Solid Tumors With NTRK, ROS1 or ALK Gene Fusion</condition>
  <arm_group>
    <arm_group_label>adult patients_Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>adult patients_Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>adult patients_Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>adult patients_Dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>adult patients_Dose 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>adult patients_Dose 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>adult patients_Dose 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>adult patients_Dose 8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SIM1803-1A</intervention_name>
    <description>SIM1803-1A will be administered orally as tablets at a given dose once daily in continuing 21-days cycles.</description>
    <arm_group_label>adult patients_Dose 1</arm_group_label>
    <arm_group_label>adult patients_Dose 2</arm_group_label>
    <arm_group_label>adult patients_Dose 3</arm_group_label>
    <arm_group_label>adult patients_Dose 4</arm_group_label>
    <arm_group_label>adult patients_Dose 5</arm_group_label>
    <arm_group_label>adult patients_Dose 6</arm_group_label>
    <arm_group_label>adult patients_Dose 7</arm_group_label>
    <arm_group_label>adult patients_Dose 8</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients with a locally advanced or metastatic solid tumor that has progressed&#xD;
             or was nonresponsive to available therapies, are unfit for standard chemotherapy or&#xD;
             for which no standard or available curative therapy exists；Proof of a malignancy&#xD;
             harboring a NTRK、ROS1 or ALK fusion；Eastern Cooperative Oncology Group (ECOG) score of&#xD;
             0 or 1 and a life expectancy of at least 3 month；Adequate hematologic, hepatic, and&#xD;
             renal function；Signed informed consent form；&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any contraindications as listed in the local approved product information；Patients&#xD;
             with unstable primary central-nervous-system tumors or metastasis, exceptions&#xD;
             possible；Pregnancy or lactation；Clinically significant active cardiovascular disease&#xD;
             or history of myocardial infarction；Participation in an investigational program with&#xD;
             interventions outside of routine clinical practice；Prior treatment with other kinase&#xD;
             inhibitor with tropomyosin receptor kinase inhibition；Active uncontrolled systemic&#xD;
             bacterial, viral, or fungal infection；Current treatment with a strong CYP3A4 inhibitor&#xD;
             or inducer；&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>shun lu, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Chest Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>zhen zhou, MD</last_name>
    <phone>021-22200000</phone>
    <email>jenniferzhou1116@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Chest Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>zhen zhou, MD</last_name>
      <phone>021-22200000</phone>
      <email>jenniferzhou1116@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 15, 2020</study_first_submitted>
  <study_first_submitted_qc>December 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2020</study_first_posted>
  <last_update_submitted>January 11, 2021</last_update_submitted>
  <last_update_submitted_qc>January 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

